experts opinion

How standardized viral vector platforms can drive better service from CDMOs

Contract Development and Manufacturing Organizations (CDMOs) offer ready-to-go platforms to solve the viral vectors and vaccines manufacturing capacity bottleneck. These platforms can help biotherapeutics developers to reach clinical trials with a consistent, regulatory-compliant and affordable product. However, CDMOs impose long-term binding contracts, forcing clients to commit to the platform until the late clinical stage, unless they pay costly licensing fees. 

At Exothera, we are designing a flexible viral vector platform that will offer our partners and customers a variety of collaboration options, adaptive solutions, and affordable licensing fees based on a checkpoint system that could help clients to choose their path at each stage without long-term binding contracts.

We spoke to three industry experts to find out how they think this could change the CDMO selection process for biotherapeutic developers.

    Experts

    • Dirk Geerts, Senior Development Scientist at Glycostem Therapeutics.
    • Sanjin Zvoni─ç. Vice President, Business Development & Practice Expert at Dark Horse Consulting.
    • Hanna P. Lesch, Chief Technology Officer at Exothera.

    Viral Vectored Gene therapies approved worldwide